Inventor · disambiguated record
Shengjiang Liu
Also filed as: LIU SHENGJIANG
7 granted patents·14 pending applications·378 citations·filing 2001–2025
85Inventor score
Top patents by PatentIndex Score
21 records- 0197US6833441B2Compositions and methods for generating chimeric heteromultimersABMAXIS INC·Filed 2001·Granted Dec 21, 2004·293 cites·38 claims
- 0295US7429652B2Compositions and methods for generating chimeric heteromultimersABMAXIS INC·Filed 2004·Granted Sep 30, 2008·78 cites·31 claims
- 0393US11898178B2Catalysis deactivated angiotensin-converting enzyme 2 (ACE2) variants and their usesAVIRMAX INC·Filed 2022·Granted Feb 13, 2024·2 cites·5 claims
- 0493US11453869B2Catalysis deactivated angiotensin-converting enzyme 2 (ACE2) variants and their usesAVIRMAX INC·Filed 2021·Granted Sep 27, 2022·4 cites·5 claims
- 0585US12441990B2Host cell including expression vector for encoding catalysis deactivated angiotensin-converting enzyme 2 (ACE2) variantsAVIRMAX INC·Filed 2024·Granted Oct 14, 2025·0 cites·2 claims
- 0673US11564392B2Methods of inactivation of viruses using n-methlyglucamide and its derivativesBAYER HEALTHCARE LLC·Filed 2018·Granted Jan 31, 2023·1 cites·13 claims
- 0772US2024196891A1Methods of inactivation of viruses using n-methylglucamide and its derivativesBAYER HEALTHCARE LLC·Filed 2023·Application pending·0 cites
- 0872US2025099622A1Compositions and methods for expressing therapeuticsAVIRMAX BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 0968US2024269327A1Compositions and methods for transgene expressionAVIRMAX BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 1068US2023143494A1Methods of inactivation of viruses using n-methylglucamide and its derivativesBAYER HEALTHCARE LLC·Filed 2022·Application pending·0 cites
- 1166US2024092866A1Compositions and methods for ocular transgene expressionAVIRMAX BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1265US2004010376A1Generation and selection of protein library in silicoFiled 2003·Application pending·0 cites
- 1363US2007037214A1Generation and selection of protein library in silicoLUO PEIZHI·Filed 2006·Application pending·0 cites
- 1461US2011124528A1Generation and affinity maturation of antibody library in silicoLUO PEIZHI·Filed 2010·Application pending·0 cites
- 1559US2024035045A1Engineered viral capsids and methods of useAVIRMAX BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1657US2025382587A1Methods for manufacturing viruses and viral particlesAVIRMAX BIOPHARMA INC·Filed 2025·Application pending·0 cites
- 1753US2003022240A1Generation and affinity maturation of antibody library in silicoFiled 2002·Application pending·0 cites
- 1852US2023335297A1Pathogen Clearance System and MethodBAYER HEALTHCARE LLC·Filed 2021·Application pending·0 cites
- 1949US2020376444A1Modified Filter Membrane and MethodBAYER HEAL THCARE LLC·Filed 2019·Application pending·0 cites
- 2046US12123028B2Viral inactivation methods for continuous manufacturing of antibodiesBAYER HEALTHCARE LLC·Filed 2019·Granted Oct 22, 2024·0 cites·11 claims
- 2142US2003064053A1Multivalent protein conjugate with multiple ligand-binding domains of receptorsFiled 2002·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →